

Novartis Pharmaceuticals Corporation

VT S.92 (Act 193, Sec.10.18 V.S.A Â§ 4637) Reporting

Overview

In Accordance with the requirements of subsection B set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A Â§ 4637) regulation, this is our 30-day post launch report of the introduction of the products listed below, into the state of Vermont.

The Product(s)

Locametz injection-solution 25 mcg

Marketing Plans

The marketing for Locametz includes education and promotion to physicians, direct to consumer promotions, other types of marketing (e.g., online platforms and education).

Pricing Plans

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
LOCAMETZ	gallium Ga 68 gozetotide	69488-0017-61	\$5,600.00	05/26/2022

Novartis considered many factors in determining the price of Locametz. Locametz is a worldwide targeted therapy leader and first in class innovated therapy, Gallium-68 labeled Locametz, can identify tumor lesions expressing the PSMA biomarker and locate where in the body tumors may have spread (eg, in soft tissue, lymph nodes, or bone), identifying patients eligible for targeted treatment with Pluvicto^{1,2}. PSMA is highly expressed in more than 80 percent of patients with prostate cancer, making it an important phenotypic biomarker for assessing the progression of metastatic prostate cancer. Patients have simplified access to the product as Novartis patient support is a comprehensive support program designed to help patients get started on treatment and stay on treatment. Factors in our pricing methodology included consideration of value delivered to the patient, healthcare system, and society, as well as existing market dynamic, and aggregate company-wide costs for research and development; manufacturing and distribution; to undertake quality measures; and ensure safety and effectiveness with ongoing pharmacovigilance for patients. No comparison to other products was used as Locametz is the first and only approved complementary diagnostic imaging agent after radiolabeling with gallium-68 for the identification of PSMA-positive lesions. Locametz was priced to the healthcare value provided by this innovative medicine.

Estimated Volume of Patients

~140K

Breakthrough Designation

No

Date of Acquisition

The date of acquisition of the product(s) is listed below.

NDC	Date of Acquisition
69488-0017-61	N/A